AbbVie Inc. $ABBV Shares Acquired by VCI Wealth Management LLC

VCI Wealth Management LLC increased its position in shares of AbbVie Inc. (NYSE:ABBV) by 36.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,506 shares of the company’s stock after purchasing an additional 3,370 shares during the quarter. VCI Wealth Management LLC’s holdings in AbbVie were worth $3,271,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in ABBV. Garde Capital Inc. raised its holdings in shares of AbbVie by 58.7% in the third quarter. Garde Capital Inc. now owns 2,354 shares of the company’s stock valued at $616,000 after buying an additional 871 shares during the last quarter. Gerber Kawasaki Wealth & Investment Management grew its holdings in AbbVie by 16.7% during the 3rd quarter. Gerber Kawasaki Wealth & Investment Management now owns 5,492 shares of the company’s stock worth $1,437,000 after acquiring an additional 786 shares during the last quarter. GRIMES & Co WEALTH MANAGEMENT LLC grew its holdings in AbbVie by 1.0% during the 3rd quarter. GRIMES & Co WEALTH MANAGEMENT LLC now owns 104,631 shares of the company’s stock worth $27,371,000 after acquiring an additional 997 shares during the last quarter. Frederick Financial Consultants LLC increased its position in AbbVie by 2.7% in the 3rd quarter. Frederick Financial Consultants LLC now owns 2,400 shares of the company’s stock valued at $628,000 after acquiring an additional 62 shares in the last quarter. Finally, Summit Wealth Group LLC Co. increased its position in AbbVie by 40.2% in the 3rd quarter. Summit Wealth Group LLC Co. now owns 4,437 shares of the company’s stock valued at $1,161,000 after acquiring an additional 1,272 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Expanded migraine partnership: AbbVie and Brise Pharmaceuticals announced a global license agreement to advance next-generation migraine treatments, potentially worth up to $757 million. The deal adds another growth opportunity to AbbVie’s neuroscience pipeline. AbbVie, Brise Expand Migraine Drug Partnership
• Positive Sentiment: Positive migraine data: A Phase 3 study published in The Lancet Neurology reportedly delivered a favorable result, supporting the commercial potential of AbbVie’s migraine portfolio. AbbVie Lands Phase 3 Migraine Study Win
• Positive Sentiment: Analyst optimism increased: Cantor Fitzgerald raised its price target to $325, while RBC, Canaccord Genuity, Leerink Partners and Morgan Stanley lifted targets to $330, $338, $342 and $346, respectively. The revisions reflect confidence in AbbVie’s immunology transition and raised outlook. Analysts Increase Forecasts on AbbVie
• Positive Sentiment: Strong operating performance: Third-quarter revenue rose 10.3% to $17.4 billion, while adjusted EPS of $3.82 exceeded expectations. Skyrizi, Rinvoq and neuroscience products are offsetting Humira’s decline, and management raised its 2026 revenue and earnings outlook. ABBV Q3 Earnings Call Highlights
• Positive Sentiment: Dividend increase: AbbVie raised its quarterly dividend 5.2% to $1.82 per share, signaling confidence in cash flow and reinforcing the stock’s income appeal.
• Neutral Sentiment: Legal win: AbbVie prevailed in a lawsuit against the U.S. Department of Health and Human Services concerning drug-price controls, potentially reducing near-term regulatory uncertainty. AbbVie Wins Drug Price Control Lawsuit
• Negative Sentiment: Transition and valuation risks remain: Humira sales continue to decline, leaving investors dependent on Skyrizi, Rinvoq and pipeline launches to sustain growth. After a sharp rally, ABBV’s elevated valuation and proximity to its 52-week high may also be prompting profit-taking despite the positive updates. AbbVie’s Humira Era Is Fading

Analyst Upgrades and Downgrades

ABBV has been the subject of a number of research analyst reports. Citigroup boosted their target price on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 15th. Rothschild & Co Redburn increased their price target on shares of AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Barclays raised their price target on shares of AbbVie from $300.00 to $325.00 and gave the company an “overweight” rating in a report on Wednesday, October 21st. Morgan Stanley boosted their price objective on shares of AbbVie from $310.00 to $346.00 and gave the stock an “overweight” rating in a research report on Monday. Finally, Oppenheimer boosted their price objective on shares of AbbVie from $244.00 to $258.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $294.67.

Insider Buying and Selling at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.06% of the stock is currently owned by company insiders.

AbbVie Stock Down 2.1%

AbbVie stock opened at $288.66 on Tuesday. The business’s 50-day simple moving average is $269.81 and its 200 day simple moving average is $237.57. The stock has a market cap of $509.99 billion, a price-to-earnings ratio of 49.68, a P/E/G ratio of 1.31 and a beta of 0.24. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $298.74.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 30th. The company reported $3.82 EPS for the quarter, topping analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The firm had revenue of $17.40 billion during the quarter, compared to analyst estimates of $17.32 billion. During the same period last year, the company earned $1.86 earnings per share. The company’s revenue was up 10.3% on a year-over-year basis. As a group, sell-side analysts expect that AbbVie Inc. will post 13.92 EPS for the current year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be paid a dividend of $1.82 per share. This represents a $7.28 dividend on an annualized basis and a dividend yield of 2.5%. This is a positive change from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date of this dividend is Friday, January 15th. AbbVie’s payout ratio is presently 119.10%.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.